Urogen Pharma (NASDAQ:URGN) Raised to “Buy” at HC Wainwright

Urogen Pharma (NASDAQ:URGN) was upgraded by equities researchers at HC Wainwright from a “neutral” rating to a “buy” rating in a report issued on Monday, MarketBeat.com reports. The brokerage presently has a $50.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 277.64% from the company’s previous close.

A number of other equities research analysts also recently weighed in on URGN. The Goldman Sachs Group lowered their target price on shares of Urogen Pharma from $16.00 to $3.00 and set a “neutral” rating on the stock in a research note on Thursday, May 22nd. Oppenheimer reduced their price target on shares of Urogen Pharma from $36.00 to $10.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 3rd. Scotiabank increased their price target on shares of Urogen Pharma from $23.00 to $47.00 and gave the company a “sector outperform” rating in a research report on Friday, June 13th. Guggenheim reiterated a “buy” rating and set a $30.00 price target (up from $15.00) on shares of Urogen Pharma in a research report on Friday, June 13th. Finally, LADENBURG THALM/SH SH started coverage on shares of Urogen Pharma in a research report on Wednesday, February 19th. They set a “buy” rating and a $31.00 price target on the stock. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $32.86.

Urogen Pharma Trading Down 7.7%

Shares of URGN opened at $13.24 on Monday. The firm’s 50 day simple moving average is $8.69 and its 200 day simple moving average is $10.07. The company has a market capitalization of $610.50 million, a P/E ratio of -4.16 and a beta of 0.40. The company has a debt-to-equity ratio of 4.77, a current ratio of 5.65 and a quick ratio of 5.47. Urogen Pharma has a 1-year low of $3.42 and a 1-year high of $18.15.

Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). The company had revenue of $20.25 million during the quarter, compared to analysts’ expectations of $22.71 million. Urogen Pharma had a negative net margin of 150.68% and a negative return on equity of 97,487.15%. Sell-side analysts forecast that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Insider Transactions at Urogen Pharma

In related news, insider Mark Schoenberg sold 5,162 shares of Urogen Pharma stock in a transaction on Monday, June 9th. The shares were sold at an average price of $7.37, for a total value of $38,043.94. Following the sale, the insider now owns 153,378 shares in the company, valued at $1,130,395.86. The trade was a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 5.10% of the company’s stock.

Institutional Trading of Urogen Pharma

Large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC bought a new stake in Urogen Pharma in the fourth quarter valued at $1,472,000. Lazard Asset Management LLC purchased a new position in Urogen Pharma during the fourth quarter valued at $67,000. Janus Henderson Group PLC purchased a new position in Urogen Pharma during the fourth quarter valued at $149,000. ProShare Advisors LLC purchased a new position in Urogen Pharma during the fourth quarter valued at $137,000. Finally, Bank of New York Mellon Corp lifted its position in Urogen Pharma by 7.3% during the fourth quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company’s stock valued at $1,001,000 after buying an additional 6,430 shares during the period. Institutional investors own 91.29% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.